|
Report Date : |
02.01.2015 |
IDENTIFICATION DETAILS
|
Name : |
LABORATORIOS ANDROMACO S.A |
|
|
|
|
Registered Office : |
Blvd. Quilin 5273 Peñalolen; Santiago; Metropolitana |
|
|
|
|
Country : |
Chile |
|
|
|
|
Date of Incorporation : |
30.08.2000 |
|
|
|
|
Legal Form : |
Sociedad Anónima |
|
|
|
|
Line of Business : |
Manufacturer of Pharmaceutical |
|
|
|
|
No. of Employee : |
761 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 1 000 000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2014
|
Country Name |
Previous Rating (30.06.2014) |
Current Rating (30.09.2014) |
|
Chile |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHILE ECONOMIC OVERVIEW
Chile has a market-oriented economy characterized by a high level of foreign trade and a reputation for strong financial institutions and sound policy that have given it the strongest sovereign bond rating in South America. Exports of goods and services account for approximately one-third of GDP, with commodities making up some three-quarters of total exports. Copper alone provides 19% of government revenue. From 2003 through 2013, real growth averaged almost 5% per year, despite the slight contraction in 2009 that resulted from the global financial crisis. Chile deepened its longstanding commitment to trade liberalization with the signing of a free trade agreement with the US, which took effect on 1 January 2004. Chile has 22 trade agreements covering 60 countries including agreements with the European Union, Mercosur, China, India, South Korea, and Mexico. Chile has joined the United States and nine other countries in negotiating the Trans-Pacific-Partnership trade agreement. The Chilean Government has generally followed a countercyclical fiscal policy, accumulating surpluses in sovereign wealth funds during periods of high copper prices and economic growth, and generally allowing deficit spending only during periods of low copper prices and growth. As of 31 December 2012, those sovereign wealth funds - kept mostly outside the country and separate from Central Bank reserves - amounted to more than $20.9 billion. Chile used these funds to finance fiscal stimulus packages during the 2009 economic downturn. In May 2010 Chile signed the OECD Convention, becoming the first South American country to join the OECD.
|
Source
: CIA |
|
Legal Name: |
Laboratorios Andromaco S.A |
|
Trade Name: |
ANDROMAC |
|
RUT: |
924480009 |
|
Date Created: |
1942 |
|
Date Incorporated: |
August 30, 2000 |
|
Legal Address: |
Blvd. Quilin 5273 Peñalolen; Santiago; Metropolitana, Chile |
|
Operative Address: |
Blvd. Quilin 5273 Peñalolen; Santiago; Metropolitana, Chile |
|
Telephone: |
56 2 2594 8000 |
|
Fax: |
56 2 2594 8000 |
|
Legal Form: |
Sociedad Anónima |
|
Email: |
|
|
Registered in: |
Chile |
|
Website: |
|
|
Manager: |
Mr. Sergio Weinstein Aranda |
|
Staff: |
761 |
|
Activity: |
Pharmaceutical Manufacturer |
|
|
|
|
BANKS |
Banco de Chile |
|
|
|
|
|
The company does not make its banking data public |
Laboratorios Andrómaco S.A. was founded in 1942 and is based in
Santiago, Chile. As of December 24, 2013, Laboratorios Andromaco S.A. operates
as a subsidiary of Grünenthal GmbH.
Laboratorios Andromaco S.A. Key Developments
Cipher Pharmaceuticals Inc. Completes Distribution and Supply Agreement
for Isotretinoin Product in Chile with Laboratorios Andrómaco S.A
Jun 18 14
Cipher Pharmaceuticals Inc. announced that it has entered into a
definitive distribution and supply agreement with Laboratorios Andrómaco S.A.
under which Cipher has granted Andrómaco the exclusive right to market, sell
and distribute Cipher's isotretinoin capsules in Chile.
Laboratorios Andrómaco S.A. operates as a pharmaceutical and diagnostic company in Chile. It is involved in the production and marketing of ethical or prescription, generic, nutrition, technology, and OTC products, as well as cosmetics. The company represents important international pharmaceuticals firms, through which it incorporates exclusive and innovative products to its offer, for disease prevention and treatment. In addition, Andrómaco plays an active role contributing to generate pharmaceutical knowledge trough the research and development of vanguard products.
|
Products/Services
description: |
The Company's products portfolio comprises such brands as Abacten,
Baxemin, Capent, Daivonex, Elcal, Flumed, Gabex, Histalen, Ibames, Kaion,
Lactulosa, Micofin, Salbutamol, Clarimir, Dermaglos and Hipoglos, among
others. |
|
Brands: |
|
|
Sales are: |
Wholesale |
|
Clients: |
ABL PHARMA COLOMBIA S A |
|
Suppliers: |
LABORATORIOS ANDROMACO SAICI |
|
Operations area:
|
National & International |
|
The company
imports from |
Colombia, Argentina |
|
The company
exports to |
Colombia, Paraguay |
|
The subject
employs |
761 employees |
|
Payments: |
Regular |
|
Products/Services
description: |
The Company's products portfolio comprises such brands as Abacten,
Baxemin, Capent, Daivonex, Elcal, Flumed, Gabex, Histalen, Ibames, Kaion,
Lactulosa, Micofin, Salbutamol, Clarimir, Dermaglos and Hipoglos, among
others. |
|
Headquarters : |
Blvd. Quilin 5273 Peñalolen; Santiago; Metropolitana, Chile |
|
Branches: |
Its facilities include two
production plants intended for the production of hormonal and non-hormonal products,
which are located in the Through its subsidiaries, the Company has operations
established in Chile, Peru, Bolivia, Ecuador, Colombia, Panama, Costa Rica,
El Salvador, the Dominican Republic, Guatemala and the British Virgin
Islands. |
|
Listed at the
stock exchange: |
YES |
|
Capital: |
USD 346 000 000 |
|
Shareholders %: |
This is a public traded company. It is a
subsidiary of: |
|
Management: |
Mr. Andres Rudolphy Fontaine, Vice-President of the Board of Directors
and Chief Executive Officer |
|
Related
Companies: |
Laboratorios Lumiere Americanos SACI |
In 2013, Grünenthal of Germany acquired 100% of Laboratorios Chile Andrómaco US $ 364.2 million.
|
USD 2012 |
|
|
Income: |
187 327 054, 6 |
|
Ebitda: |
34 298 258,9 |
|
Results: |
13 665 565,1 |
|
Total Equity: |
90 986 883,8 |
|
FINANCIAL
FIGURES FOR 2013 CURRENCY: M$ Cash
2, 933,995 |
|
|
Exports US$ |
|
|
Year |
Total |
|
30,094,094 |
|
|
2012 |
28,690,473 |
|
2011 |
37,942,637 |
|
2010 |
30,565,891 |
|
2009 |
27,701,278 |
|
2008 |
30,077,239 |
|
|
|
|
|
|
|
Imports in US$ |
|
|
Year |
Total |
|
14,448,285 |
|
|
2012 |
14,046,866 |
|
2011 |
12,454,283 |
|
2010 |
15,216,551 |
|
2009 |
9,198,320 |
|
2008 |
11,344,610 |
There are no legal filings registered for the subject
|
Maximum Credit
Provided |
USD 1 000 000 |
Laboratorios Andrómaco S.A. operates as a pharmaceutical and diagnostic
company in Chile.
It has more than 50 years of experience in the market with a large size
structure.
The company has been recently in 2013 by a German group for a millionaire
amount.
There are no negative for the subject.
|
DEBTS |
Controlled |
|
PAYMENTS |
Regular |
|
CASH FLOW |
Good |
|
SUGGESTED CREDIT
LINE |
USD 1 000 000 |
|
NAME |
NA |
|
POSITION |
NA |
|
COMMENTS |
The receptionist transferred our call to the manager but we reached
his answering machine. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.63.28 |
|
|
1 |
Rs.98.38 |
|
Euro |
1 |
Rs.76.30 |
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
DPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.